$KD

Kyndryl restated financials citing internal control weaknesses, triggering 55% stock decline and departures of CFO, General Counsel, and Comptroller. SEC investigating disclosure gaps.

Kyndryl faces securities fraud lawsuit after CFO and General Counsel departed, triggering 54.9% stock drop. SEC investigating cash management and internal control weaknesses.

Kyndryl faces securities lawsuit after disclosing internal control weaknesses and delayed 10-Q filing. Stock dropped 21.8% following CFO and General Counsel departures.

Four major companies face securities fraud lawsuits for misleading investors on AI spending, financial disclosures, and manufacturing claims. Investor filing deadlines approaching.

Vistagen Therapeutics shareholders must file for lead plaintiff status by March 16, 2026 in securities fraud lawsuit alleging false statements and undisclosed risks.

Kyndryl faces securities lawsuit after 55% stock plunge following disclosure of internal control weaknesses, delayed filings, executive departures, and SEC inquiry.

Kyndryl faces class action lawsuit for allegedly issuing false financial statements and maintaining inadequate accounting controls, following a 50% stock drop in February 2026.

Kyndryl faces class action lawsuit alleging false financial statements and internal control weaknesses from August 2024 to February 2026, affecting investors who purchased securities during this period.

Kyndryl Holdings faces securities fraud lawsuit alleging material misrepresentations about cash management and internal financial controls, with delayed quarterly filings raising governance concerns.

Kyndryl shares dropped 55% after accounting review revealed cash management issues. CFO and General Counsel departed amid SEC inquiry and fraud lawsuit filing.

Kirby McInerney LLP filed securities fraud lawsuit against Kyndryl Holdings for alleged financial misstatements and inadequate internal controls. Stock plummeted 55% after SEC scrutiny.

Schall Law Firm filed a securities class action against Kyndryl for allegedly making false financial disclosures and failing to maintain proper internal controls between August 2024 and February 2026.

Kyndryl stock plummets 55% after disclosing internal control weaknesses, executive departures, and SEC investigation, triggering securities lawsuit for alleged material misrepresentations.

Law firm sues Kyndryl for alleged financial misstatements and internal control failures from August 2024-February 2026. Affected investors can join the class action litigation.

Kyndryl faces securities class action after disclosing internal control weaknesses, CFO/General Counsel departures, and 55% stock decline. Lead plaintiff deadline is April 13, 2026.

Kyndryl Holdings faces securities lawsuit alleging false financial statements and inadequate internal controls, with shareholders from August 2024-February 2026 eligible to join the class action.

Kyndryl faces securities fraud lawsuit over alleged misrepresentations. Stock plunged 55% after February disclosure of internal control weaknesses. Investors have until April 13 to join class action.

Kyndryl stock surged 9.8% after validating financial results and confirming no restatement needed, easing investor concerns over internal control weaknesses disclosed in February.

Tech giants spend $400B on AI infrastructure, creating winners with strong balance sheets and losers burdened by debt in this capital-intensive race.

Kyndryl investors face April 13 deadline to become lead plaintiff in securities class action over financial reporting failures and misstatements.